Aevi Genomic Medicine LLC

Aevi Genomic Medicine — FY2017 Earnings Presentation

24 slides from Aevi Genomic Medicine's earnings presentation, Mar 13, 2018

  1. Slide 1: 2017 Year-end Results and Corporate Update

    © 2018, Aevi Genomic Medicine NASDAQ: GNMX 2017 Year - end Results and Corporate Update March 13, 2018

  2. Slide 2: Forward-Looking Statement

    © 2018, Aevi Genomic Medicine 2 Forward - Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operating and financi

  3. Slide 3: Agenda

    © 2018, Aevi Genomic Medicine 3 Agenda • AEVI - 001 update • AEVI - 002 update • Financial update • Pipeline • Conclusion

  4. Slide 4: AEVI-001 in ADHD Overview

    © 2018, Aevi Genomic Medicine AEVI - 001 in ADHD Overview

  5. Slide 5: CAG Breakthrough Discovery

    CAG Breakthrough Discovery • 10 fold increased frequency of copy number variations (CNV’s) in the mGluR gene network detected in ADHD population vs. normal controls • These mutations were found in several related neuropsychiatric diseases 5 Research led by Dr. Hakon Hakonarson indicated ~20% of ADHD

  6. Slide 6: AEVI-001: Potential for Superior Product Profile

    © 2018, Aevi Genomic Medicine 6 AEVI - 001: Potential for Superior Product Profile 1. Ogasawara et al. (1999) Pharmacol Biochem Behav , 64(1):41 - 52. 2. Nakagawa et al. (1988) Jpn J Pharmacol , 46(Suppl.): Abst O - 258. 3. Nakagawa et al. (1990) Jpn J Pharmacol , 52(Suppl. I): Abst P - 491. 4. Oka

  7. Slide 7: AEVI-001: ADHD Development Program

    © 2018, Aevi Genomic Medicine Confidential | 7 AEVI - 001: ADHD Development Program Phase 3 mGluR + Genetic Subset ADHD N=TBD, Ages 6 - 12 Phase 3 mGluR + Genetic Subset ADHD N=TBD, Ages 6 - 17 Phase 2 (ASCEND) (Recruiting) mGluR+ Genetic Subset ADHD N=42 - 64, Ages 6 - 17 ADHD Phenotype / Genotype

  8. Slide 8: SAGA Responder Analysis Summary

    © 2018, Aevi Genomic Medicine 8 SAGA Responder Analysis Summary • Post - hoc analysis of patients responding to AEVI - 001 revealed a 9 - gene subset predictive of response to AEVI - 001 – accounts for approximately 10% of pediatric ADHD patients. 1 • Novel discovery: prevalence of CNTN4 mutations i

  9. Slide 9: Comparative Analysis of 9-Gene Subset from the SAGA Trial

    © 2018, Aevi Genomic Medicine 9 Comparative Analysis of 9 - Gene Subset from the SAGA Trial Change in ADHD - RS B a s e l i n e W e e k 1 ( 1 0 0 m g B I D ) W e e k 2 ( 2 0 0 m g B I D ) W e e k 3 ( 4 0 0 m g B I D ) W e e k 4 ( O p t i m i z e d D o s e ) W e e k 5 ( M a i n t e n a n c e D o s e

  10. Slide 10: Frequency of Responder Genes to AEVI-001

    © 2018, Aevi Genomic Medicine 10 C N T N 4 N e u r o G e n e A G R M G e n e A G R M G e n e B N e u r o G e n e B N e u r o G e n e C N e u r o G e n e D N e u r o G e n e E N e u r o G e n e F 0 1 2 3 4 5 P e r c e n t a g e o f T o t a l A D H D Frequency of Responder Genes to AEVI - 001 • Total

  11. Slide 11: AEVI-001-202 (ASCEND) Trial Design

    © 2018, Aevi Genomic Medicine 11 Dose - optimization Period (4 weeks) Screening Period (up to 4 weeks inclusive of washout, if applicable) Dose Maintenance Period (2 weeks) Follow - up Call (1 week) Visit #: 1 2 3 4 5 6 7 8/ET Dose: 100 mg BID, 200 mg BID, or 400 mg BID, Dose optimization based on r

  12. Slide 12: 9-Gene Subset Responders: ADHD Total Addressable Market

    © 2018, Aevi Genomic Medicine 12 9 - Gene Subset Responders: ADHD Total Addressable Market • Overall US ADHD Market – US market sales: ~$11.1B 1 and growing at ~2 % CAGR 1 – Stimulants dominate market: ~90 % of sales 1 – ~6M pediatric (ages 6 - 17) patients and ~10M adult patients in US 2,3 • 9 - Ge

  13. Slide 13: AEVI-001 in Autism Spectrum Disorder (ASD) Overview

    © 2018, Aevi Genomic Medicine AEVI - 001 in Autism Spectrum Disorder (ASD) Overview

  14. Slide 14: Aevi-001 ASD Program: Treatment of Co-morbid ADHD in ASD

    © 2018, Aevi Genomic Medicine 14 Aevi - 001 ASD Program :Treatment of Co - morbid ADHD in ASD • High unmet need; no drugs approved for “core symptoms” or ADHD • Only 2 drugs approved: atypical antipsychotics for irritability in ASD • High degree of ADHD comorbidity in ASD patients (up to 80 - 85%) 1

  15. Slide 15: ASD Signal Finding Trial Overview

    © 2018, Aevi Genomic Medicine 15 ASD Signal Finding Trial Overview Aevi strategy: Study AEVI - 001 in high functioning ASD patients (IQ ൒ ͹Ͳ ሻ with comorbid ADHD and mGluR+ mutations. • Planned POC study – Inclusion criteria: 9 gene subset, ASD with comorbid ADHD, 6 - 17 years of age, IQ ൒ ͹Ͳ • Desi

  16. Slide 16: AEVI-002 Program in Severe Pediatric Onset Crohn's Disease Overview

    © 2018, Aevi Genomic Medicine AEVI - 002 Program in Severe Pediatric Onset Crohn’s Disease Overview

  17. Slide 17: AEVI-002: Anti-LIGHT mAb Program

    © 2018, Aevi Genomic Medicine 17 AEVI - 002: Anti - LIGHT mAb Program • First - in - Class Biologic from Kyowa Hakko Kirin – Initial development in Severe Pediatric Onset IBD – Phase 2 human monoclonal antibody • Program Update – Study design: 8 – 12 patient study in refractory Crohn’s Disease patie

  18. Slide 18: AEVI-005 Program Overview

    © 2018, Aevi Genomic Medicine AEVI - 005 Program Overview

  19. Slide 19: AEVI-005: Novel Orphan Program

    © 2018, Aevi Genomic Medicine 19 AEVI - 005: Novel Orphan Program • Collaboration with Kyowa Hakko Kirin • First - in - class monoclonal antibody targeting a specific cell surface marker implicated in an ultra - orphan auto - immune pediatric disease – Preclinical stage • Aevi - led translational wo

  20. Slide 20: Novel Approach: Matching Molecules to Target Indications

    © 2018, Aevi Genomic Medicine 20 Novel Approach: Matching Molecules to Target Indications Partnered with KHK • Novel mechanism/molecule from partner • Aevi identifies appropriate biological pathways for potential therapeutic intervention in known pediatric rare/orphan diseases with potential to expa

  21. Slide 21: Q4 and Full Year 2017 Financial Update

    © 2018, Aevi Genomic Medicine Q4 and Full Year 2017 Financial Update

  22. Slide 22: Q4 and Full Year 2017 Financial Update

    © 2018, Aevi Genomic Medicine 22 Q4 and Full Year 2017 Financial Update  $33.4M cash and cash equivalents at 12/31/2017  Current cash resources estimated to fund operations into early 2019, including through the receipt of:  Top - line data from AEVI - 001 in the ASCEND trial in mGluR+ Genetic Su

  23. Slide 23: Aevi Genomic Medicine Pipeline

    © 2018, Aevi Genomic Medicine Confidential | 23 Aevi Genomic Medicine Pipeline Compound Indication Preclinical Phase 1 Phase 2 Phase 3 AEVI - 001 mGluR+ Genetic Subset in ADHD (pediatric, age 6 - 17) mGluR+ Genetic Subset in ASD AEVI - 002* (anti - LIGHT mAb) Severe Pediatric Onset Crohn’s Disease A

  24. Slide 24: Thank you

    © 2018, Aevi Genomic Medicine 24 Thank you

Aevi Genomic Medicine — FY2017 Earnings Presentation on 6ix